Oral News and Research

RSS

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma.

8 Dec 2015

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).

8 Dec 2015

Merus reports revenues of $49.0 million for fiscal 2015

Merus Labs International Inc. is pleased to report its financial results for fiscal year ending September 30, 2015.

7 Dec 2015

Scientists decipher details of cloaking proteins that protect the toxin that causes botulism

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory and collaborators at Stony Brook University and the Institute of Advanced Sciences in Dartmouth, Massachusetts, have discovered new details about how "cloaking" proteins protect the toxin that causes botulism, a fatal disease caused most commonly by consuming improperly canned foods.

7 Dec 2015

Research shows significant step toward improving outcomes, reducing treatment burden for SCD patients

Emerging therapies and promising new insights in the treatment of sickle cell disease represent a significant step toward improving outcomes and reducing the treatment burden for affected children and adults. Studies reporting these advances will be presented today at the 57th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2015

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

OphthaliX Inc., a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd., announced today that it has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.

7 Dec 2015

Tooth decay can be prevented without the need for traditional 'fill and drill' approach

A University of Sydney study has revealed that tooth decay (dental caries) can be stopped, reversed, and prevented without the need for the traditional 'fill and drill' approach that has dominated dental care for decades.

7 Dec 2015

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.

7 Dec 2015

Age doesn't matter when considering HCT for patients with MDS, study reveals

Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to 64.

7 Dec 2015

Researchers partner to help personalize cancer care

Researchers at the University of Iowa College of Dentistry are partnering with a private company to develop computer simulations that can help personalize cancer care by predicting how a patient will respond to a drug treatment.

7 Dec 2015

Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Research to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition reveals genetic variants that are associated with disease severity and treatment-related complications in children with blood diseases.

7 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

Phase II study hints at oestriol effect in multiple sclerosis

Oestriol, given in combination with glatiramer acetate, may reduce the risk of relapse in women with relapsing–remitting multiple sclerosis, suggest findings from a phase II trial.

3 Dec 2015

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon Pharmaceuticals, Inc. announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study.

1 Dec 2015

Taking estriol along with conventional medications helps RRMS patients avoid relapses

Taking the pregnancy hormone estriol along with their conventional medications helped patients with relapsing-remitting multiple sclerosis (RRMS) avoid relapses, according to results of a Phase II randomized, placebo-controlled study led by UCLA researchers.

1 Dec 2015

Oral News and Research

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Merus reports revenues of $49.0 million for fiscal 2015

Scientists decipher details of cloaking proteins that protect the toxin that causes botulism

Research shows significant step toward improving outcomes, reducing treatment burden for SCD patients

New approaches to treating leukemia, lymphoma and myeloma

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

Tooth decay can be prevented without the need for traditional 'fill and drill' approach

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Age doesn't matter when considering HCT for patients with MDS, study reveals

Researchers partner to help personalize cancer care

Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Phase II study hints at oestriol effect in multiple sclerosis

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Taking estriol along with conventional medications helps RRMS patients avoid relapses

Combining two blood sugar tests may improve prediabetes detection, study finds

MPP collaborates with University of Liverpool to accelerate development of HIV nanomedicines

Seaweed extract shows promise in treating H. pylori-related diseases, gastric cancer

Ultra-performance chromatography test aids bosutinib plasma quantification

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News